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Background: Depression is an important cause of disability among children and adolescents. Depression screening
is one possible method for managing depression, and screening programs have been initiated in some school and
medical settings. However, in 2005, the Canadian Task Force on Preventive Health Care and the United Kingdom
National Institute of Clinical Excellence did not recommend depression screening among children and adolescents.
By contrast, in 2009, the United States Preventive Services Task Force recommended that all adolescents, but not
younger children, be screened for depression in medical settings with integrated depression management services,
although no trials of screening were identified. The objectives of this systematic review are to evaluate in children
and adolescents the accuracy of depression screening tools; depression treatment efficacy; whether depression
screening improves depression outcomes; and potential harms related to depression interventions and screening.
Methods/design: Data sources will include the bibliographic databases MEDLINE, Cochrane CENTRAL, PsycINFO,
EMBASE, LILACS and Web of Science, supplemented by reference harvesting of eligible articles, relevant systematic
reviews, relevant guidelines and recommendations, and selected journals, and by searches for unpublished studies.
Eligible studies will report data for children and adolescents aged 6 to 18 years. Eligible diagnostic accuracy studies
must compare a depression screening tool to a validated diagnostic interview for major depressive disorder and
report diagnostic accuracy data. Eligible treatment studies must be randomized controlled trials of pharmacological,
psychotherapeutic, or other depression treatments commonly available for children and adolescents in pediatric,
primary-care, and family medicine settings. Eligible screening studies must be randomized controlled trials that
compare depression outcomes between children or adolescents who underwent depression screening versus those
who did not. Studies of harms will include randomized controlled trials and observational studies that evaluate
harms from depression screening or treatment. Two investigators will independently review titles and abstracts,
followed by full article review. Disagreements will be resolved by consensus. Two investigators will independently
extract the data, with discrepancies resolved via consensus.
Discussion: The proposed systematic review will determine whether there is sufficient evidence of benefits in
excess of harms and costs to support screening for depression in childhood and adolescence.
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Depression in children and adolescents is a disabling
condition that is associated with long-term mental and
physical health problems [1]. Screening for depression
is one possible solution to improve depression man-
agement. In 2005, however, the Canadian Task Force
on Preventive Health Care (CTFPHC) determined that
there was not sufficient evidence on health outcomes
from depression screening to recommend the practice
among children and adolescents in primary health care
settings [2]. Consistent with this, a 2005 guideline
from the United Kingdom’s National Institute for
Health and Clinical Excellence (NICE) concluded that
universal screening was not advised based on available
evidence [3]. In 2009, by contrast, the United States
Preventive Services Task Force (USPSTF) concluded
that adolescents, but not younger children, should be
routinely screened for depression in primary health
care settings ‘when systems are in place to ensure ac-
curate diagnosis, psychotherapy (cognitive-behavioral
or interpersonal), and follow-up’ (page 1223) [4]. This
recommendation was made based on a systematic re-
view of the literature through May 2006 even though,
as the USPSTF recognized, there was little data on the
accuracy of screening tools and no data to compare
health outcomes between screened and unscreened
adolescents [1]. In the more than 5 years since that re-
view, a substantial amount of research relevant to de-
pression screening in children and adolescence has
been published.
Screening is potentially costly in health care resources
and has the potential to cause harm to some children
and adolescents who may be diagnosed or treated in-
appropriately. An important empirical question is
whether screening, given these concerns, would be more
effective than alternative care models that do not rely on
universal screening. As described in a recent critique of
calls for depression screening, there are a number of rea-
sons why simply assuming that depression screening
would result in more benefit than harm may not be rea-
sonable, including high false positive rates if screening
tools are not sufficiently precise, generally small depres-
sion treatment effects, and the inconsistent quality of
routine care that is often provided [5]. Thus, the object-
ive of the proposed systematic review is to evaluate the
mental health effects of screening children and adoles-
cents aged 6 to 18 years for major depressive disorder
(MDD) in medical or community settings. To do this,
we identified the following key questions based on well-
established criteria delineated by the World Health
Organization [6] and the United Kingdom National
Screening Committee [7], as well as the methodological
framework of the USPSTF for evaluating screening pro-
grams [8]:Key Question #1: What is the accuracy of depression
screening instruments to detect cases of MDD among
(a) children and (b) adolescents?
Key Question #2: Is treatment of MDD during (a)
childhood and (b) adolescence effective in improving
symptoms of depression?
Key Question #3: Is depression screening during (a)
childhood and (b) adolescence more effective than
usual care in (i) improving depressive symptoms or (ii)
reducing the number of MDD diagnoses?
Key Question #4: What are the potential harms
associated with depression screening, including
treatment, during (a) childhood and (b) adolescence?
Major depressive disorder in children and adolescents
Depression is primarily characterized by the core symp-
toms of persistent sad mood or irritability and/or a loss
of interest or pleasure in activities that are normally
enjoyed. Among children and adolescents, irritability
may be more prominent than sad mood, and tantrums
and other disruptive behavior may also be important
markers. In North America, MDD is diagnosed among
children and adolescents based on criteria established by
the American Psychiatric Association and delineated in
the 4th Edition of the Diagnostic and Statistical Manual
(DSM-IV) [9]. Criteria for a diagnosis of MDD include
having at least five of nine depressive symptoms for 2
weeks or more, at least one of which must be depressed
mood, including irritability, or loss of interest in activ-
ities. Symptoms must cause significant distress or im-
pairment in daily function. MDD should be
distinguished from bipolar disorder, which is character-
ized by abnormal and disruptive elevated moods, in
addition to depression. The DSM-IV also includes dys-
thymic disorder, which is a longer lasting, but less se-
vere, mood manifestation than MDD, as well as minor
depressive disorder, which requires only two, rather than
five, depressive symptoms. This review, consistent with
earlier reviews by the CTFPHC [2] and the USPSTF [1]
will assess evidence relevant to screening for MDD, but
not dysthymic disorder or minor depression, for which
treatment options and efficacy are much less well deli-
neated. It will also include studies relevant to screening
for depression based on the International Classification
of Diseases (ICD) definition of depression, which is simi-
lar to the DSM-IV definition [10].
Prevalence and burden of depression in children and
adolescents
A 2006 meta-analysis that synthesized data from over
60,000 adolescents aged 13 to 18 years estimated the
point prevalence of MDD to be 5.6% in the community
with rates slightly higher among girls than boys [11]. In
Canada, a study of almost 18,000 respondents to the
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that 4.8% of boys and 8.7% of girls had an episode of
MDD in the past year. Among youth aged 12 to 14
years, the rates were 2.7% for boys and 2.6% for girls.
For adolescents aged 15 to 19 years, 6.1% of boys and
12.5% of girls had experienced at least one episode [12].
Compared to community samples, in medical settings
the rate may be up to twice as high [13]. Some research
has suggested that the lifetime prevalence of an episode
of MDD among adolescents may be as high as 20%
[1,14,15]. In Canada, however, a study that used data
from the Canadian Community Health Survey Cycle 1.2
reported a lifetime prevalence rate among almost 3,000
adolescents aged 15 to 19 years of 7.6% for MDD, in-
cluding 4.3% for males and 11.1% for females [16].
Among youth under age 13, the point prevalence of
MDD has been estimated to be approximately 3% [11].
MDD in childhood and adolescence is associated with
many negative outcomes, including behavioral problems
and poor school performance, early pregnancy, and
impaired social, work, and family functioning in adoles-
cence and into adulthood [1]. Many studies have shown
that patients with depression in adulthood had at least
one episode of MDD in childhood or adolescence, and
there is a high rate of recurrence among youth with
MDD [1,15,17-19]. Despite this substantial burden, rela-
tively few children and adolescents with depression re-
ceive treatment [20-22].
What is depression screening and when should it be
recommended?
Screening is a preventive strategy that is traditionally
used to detect disease in patients who otherwise have no
signs or symptoms. Screening programs are premised on
the assumption that early detection of disease will enable
earlier and more effective intervention. Unlike screening
for most other medical diseases, however, screening for
depression does not seek to achieve early identification
of pre-symptomatic cases that will subsequently evolve
into psychiatric disorder. Rather, screening for depres-
sion involves the use of depression symptom question-
naires or small sets of questions about depression to
identify patients who may have current depression, but
who have not sought treatment and whose depression
has not already been recognized by health care provi-
ders. Patients identified as possible cases need to be fur-
ther assessed and, if appropriate, offered treatment.
Depression screening is potentially useful only to the ex-
tent that it improves patient outcomes beyond any treat-
ment that is provided as part of standard care. Thus, to
be successful, a screening program must identify a sig-
nificant number of depressed patients who are not
already diagnosed with depression, engage those patients
in treatment, and obtain sufficiently positive treatmentresults to justify costs and potential harms from screen-
ing [5].
In 1968, the World Health Organization issued a re-
port that delineated criteria to determine whether condi-
tions are suitable for screening [6], and the main
elements of those criteria continue to be used today
[23]. Generally, it is reasonable to consider screening
when the condition in question is important and preva-
lent, can be effectively treated, and cannot be readily
detected without screening. Further, screening methods
should be accurate and carry only a tolerably small risk
of false positive results, which could lead to unnecessary
diagnostic testing, adverse effects, costs of inappropriate
treatment, and to sequelae of being incorrectly labeled,
such as stigma. False reassurance for false negatives may
also need to be considered in some circumstances. The
principal criterion is that there must be evidence that
benefits from screening outweigh potential harms.
Ideally, benefits in excess of potential harms should be
demonstrated consistently in well-conducted rando-
mized controlled trials (RCTs) with sufficiently long
follow-up to cover the time horizon of important
patient-oriented outcomes.
Current practices in depression screening in childhood
and adolescence
Studies from community [24] and health maintenance
organization [25] settings in the United States published
in 2000 and 2001 suggested that 40% to 60% of adoles-
cent patients may be screened for depression based on
physician report, but this number fell to only 3% when
medical charts were examined for documentation of
screening [24]. More recently, TeenScreen, an American
organization based at Columbia University, has aggres-
sively promoted widespread mental health screening for
adolescents and has reported that they received more
than 400,000 requests for screening questionnaires from
schools, primary-care physicians and managed-care
organizations in 2010 alone [26]. There are numerous
reports of mental health screening supported by TeenSc-
reen being conducted routinely in medical practices
and across entire school districts in the United States
[27-29]. In Canada, the governments of Alberta and
Manitoba, for instance, have called for widespread
depression screening in school settings as part of long-
term plans to improve youth mental health [30,31].
Existing guidelines and recommendations
In Canada, the last guideline statement on the topic
was a CTFPHC recommendation from 2005 [2]. The
CTFPHC recommendation focused on adult depression,
but noted that, consistent with previous findings from
the USPSTF, there was not enough evidence to support
a recommendation for screening in child or adolescent
Thombs et al. Systematic Reviews 2012, 1:58 Page 4 of 8
http://www.systematicreviewsjournal.com/content/1/1/58medical care settings. Similarly, a 2005 NICE guideline
on depression management for children and youth in
the United Kingdom emphasized the importance of bet-
ter and more consistent care, but concluded that the evi-
dence needed to support a screening recommendation
was not available [3]. More recently, in 2009, the
USPSTF issued a recommendation that adolescents in
medical settings should be screened for depression in
primary-care settings when integrated care systems are
in place to ensure accurate diagnosis, competent psycho-
therapeutic and medical support, and follow-up [4]. The
recommendation document focused on the prevalence
and burden of depression among adolescents, as well as
the existence of screening tools and treatments, but not
on evidence from any RCT that mental health outcomes
improved among youth who were screened compared
with youth who were not screened for depression [4].
Calls for depression screening have gone beyond medical
settings. The 2003 United States President’s New Free-
dom Commission on Mental Health called for screening
in primary medical care, school, and child welfare set-
tings as the key to reducing the community burden of
depression [32], and school-based screening programs
have been implemented in Canada [30]. Existing guide-
lines and recommendations, however, have not directly
addressed whether school-based screening outside of the
context of health care settings is recommended.
Previous systematic reviews and meta-analyses
A number of reviews have assessed the accuracy of
screening tools for detecting MDD, the efficacy of treat-
ments, and harms that may be associated with depres-
sion treatment in children or adolescents (see Additional
file 1). Only one review [1], a United States Agency for
Healthcare Research and Quality (AHRQ) report, which
was done in conjunction with a USPSTF guideline [4],
has assessed the various components of a depression
screening program for children or adolescents (accurate
screening tools, effects of treatment, effects of screening,
potential harms) and whether there was evidence that
mental health outcomes were better for screened versus
non-screened children and adolescents. The review was
published in 2009, but only included studies through a
search that was done through May 2006. The review
included nine studies on the accuracy of six different de-
pression screening tools, but reported that all had ser-
ious methodological flaws, including non-random
patient selection, excessive delays between administra-
tion of screening tools and diagnostic interviews, high
levels of attrition, poor reporting of methods and results,
and small samples. No studies were rated as being of
good quality. The review identified 18 fair- to good-
quality RCTs on treatment for MDD with psychother-
apy, medication, or a combination of psychotherapy andmedication, and concluded that treatments were gener-
ally effective, but that not all medications appeared to
work well. There were no studies identified that exam-
ined mental health outcomes among children or adoles-
cents who were screened compared to children and
adolescents who were not screened.
Methods/design
This systematic review has been funded by the Canadian
Institutes for Health Research (Funding Reference Num-
ber KA1 – 119795). The protocol has been registered in
the PROSPERO prospective register of systematic
reviews (CRD42012003194).
The review methodology was designed to be consistent
with reporting guidelines described in the Meta-analysis
of Observational Studies in Epidemiology statement [33]
and the Preferred Reporting Items for Systematic
Reviews and Meta-analyses statement [34,35]. Key ques-
tions for this systematic review are based on the
USPSTF analytic framework [8,36]. The USPSTF logic
model describes a process for determining whether
screening benefits likely outweigh harms, including the
specific populations, screening procedure, and health
outcomes to be considered [8]. The model assumes that
patients with undetected depression undergo screening,
which classifies patients as cases or non-cases of MDD,
and that the evaluation of the accuracy of screening tests
is a key component. Treatment studies are evaluated to
determine the degree to which they improve symptoms
of depression. Trials of actual screening programs, in
which health outcomes are evaluated for screened versus
unscreened children and adolescents are, if they exist,
the final standard by which the value of screening can
be tested in terms of its ability to improve depression
outcomes and produce benefits to children and adoles-
cents that exceed potential harms from screening.
Search strategy
Four distinct sets of searches will be conducted, one for
Key Question #1 (accuracy of screening tools), one for
Key Question #2 (effects of treatment), one for Key
Question #3 (effects of screening), and one for Key
Question #4 (harms). To identify studies relevant to
Key Question #1 (accuracy of screening tools), the
MEDLINE, EMBASE, PsycINFO, HAPI, and LILACS
databases will be searched. For Key Questions #2 (effects
of treatment), #3 (effects of screening), and #4 (harms
of screening), the MEDLINE, EMBASE, PsycINFO,
Cochrane CENTRAL, and LILACS databases will be
searched. All search strategies have been peer-reviewed.
There will be no language restrictions. See Additional
file 2 for specific search terms that will be used.
Searches will be run from January 2006 to the present
because an AHRQ systematic review on depression
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May 2006. Eligible studies from that review will be
included in the present review. For the effects of depres-
sion treatment, the previous AHRQ review [1] included
only studies on the effects of selective serotonin re-
uptake inhibitors (SSRIs) and psychotherapy. However,
serotonin-norepinephrine reuptake inhibitors (SNRIs),
other non-SSRIs (bupropion, mirtazapine, trazodone),
and exercise are also treatments for depression that may
be commonly used with children or adolescents in gen-
eral pediatric settings or primary-care and family medi-
cine settings. Thus, for Key Question #2 (effects of
treatment), an additional search with no date restriction
will be run for studies on the effects of SNRIs, a select
group of non-SSRIs (bupropion, mirtazapine, trazodone),
and exercise.
In addition, manual searching will be done for the
period of 3 months prior to the final database search on
the references of eligible original articles, relevant sys-
tematic reviews and meta-analyses, and selected jour-
nals, including journals in psychiatry, psychology, and
pediatrics. To identify unpublished or ongoing trials, we
will use methods that include reviewing trial registries
and results databases (for example, ClinicalTrials.gov),
pharmaceutical industry trial registries and results data-
bases, regulatory agency online databases, regulatory
agency submissions, litigation documents, and confer-
ences abstracts, as well as contacting trialists and spon-
sors for unpublished or ongoing trials [37].
Identification of eligible studies
Eligible studies will include children and adolescents
aged 6 to 18 years. We will include studies conducted in
general medicine clinics, schools, and community set-
tings. Studies including medically ill children are eligible.
Studies of college and university populations will be
excluded, as college and university students have a dif-
ferent pathway to mental health treatment than adoles-
cents under their parents' care.
Key Question #1 (accuracy of screening tools): Studies
on the accuracy of screening tools will be included if
they compared a screening instrument with a valid
criterion standard, defined as a DSM diagnosis of MDD
or an ICD diagnosis of depressive episode based on a
validated diagnostic interview procedure, and if they
reported data allowing determination of sensitivity and
specificity, positive predictive value, and negative
predictive value. Examples of validated psychiatric
interviews that have been used in assessments of
children or adolescents include, but are not limited to,
the Composite International Diagnostic Interview, the
Diagnostic Interview for Children and Adolescents, the
Revised Diagnostic Interview Schedule for Children,and the Schedule for Affective Disorders and
Schizophrenia for School-Aged Children. Studies that
assess broader diagnostic categories, such as any
depressive disorder or dysthymia, will be included only
if they report data for MDD separately. Studies must
administer the screening tool and the diagnostic
assessment within 2 weeks of each other to be eligible.
Studies in which only parent- or teacher-completed
measures, but no child or adolescent self-report
measures, are compared to a diagnosis of MDD will be
excluded. Studies will be excluded if a cutoff score
above a threshold on a depression screening tool is
used as an eligibility criterion to receive assessment for
MDD with a validated structured interview. Studies
conducted in high-risk populations where many or
most children and adolescents may have a psychiatric
disorder, such as in psychiatric or youth-protection
settings, will be excluded.
Key Question #2 (effects of treatment): Studies on
treatment will include RCTs with placebo or usual care
controls that evaluated pharmacological,
psychotherapeutic, or other interventions that would
typically be available to children or adolescents in
general pediatric settings or primary-care and family
medicine settings as treatment for depression as
diagnosed with a validated psychiatric interview and
DSM criteria for MDD or ICD criteria for a depressive
episode. Specifically, eligible interventions will include
SSRIs (fluoxetine, sertraline, paroxetine, citalopram,
escitalopram, and fluvoxamine), SNRIs (venlafaxine,
duloxetine, desvenlafaxine), other non-SSRIs prescribed
for children or adolescents with depression (bupropion,
mirtazapine, trazodone), psychotherapy, educational
interventions, and exercise. We will require, as an
eligibility criterion, a DSM diagnosis of MDD or ICD
diagnosis of depressive episode based on a valid
diagnostic interview because unassisted clinician
diagnoses have poor reliability and because a large
proportion of patients scoring above cutoffs on self-
report questionnaires do not have MDD. Head-to-head
trials of different interventions without a comparison to
usual care or placebo are not eligible.
Key Question #3 (effects of screening): Eligible studies
will be RCTs that compared depression outcomes
between children or adolescents who underwent
depression screening and those who did not. Studies in
which comprehensive depression care programs were
provided to children or adolescents with depression as
part of the screening program will be included if
children and adolescents in the unscreened group
could also access these treatment programs if identified
as depressed by means other than screening.
Otherwise, it will not be possible to disaggregate effects
of screening from effects of providing comprehensive
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recognition and treatment will be noted, but not
included as depression outcomes. This is because
increased treatment is not a benefit and, if improved
depression outcomes are not obtained, exposes children
and adolescents to costs and potential harms of
treatment without benefit. Screening is defined per the
United Kingdom National Screening Committee’s
definition. Thus, eligible screening trials had to include
a case identification strategy based on an a priori
defined cutoff score on a depression screening tool to
make decisions regarding further assessment or
treatment.
Key Question #4 (harms): Studies that document
harms from depression treatment or screening will
include RCTs, as well as observational studies.
Two investigators will independently review titles and
abstracts for eligibility with full-text review of articles
identified as potentially eligible by one or both. Dis-
agreements after full-text review will be resolved by con-
sensus. Chance-corrected agreement will be assessed
with Cohen’s κ. See Additional file 3 for the coding
manual.
Data extraction and outcomes
Two reviewers will independently extract relevant data
from each eligible article and enter the data directly into
formatted Excel spreadsheets. Entries will be compared
for accuracy and any discrepancies will be resolved by
consensus. Authors of original studies will be contacted
if necessary to clarify inconsistencies in reported results.
See Additional file 4 for variables included in data ex-
traction templates.
Key Question #1 (accuracy of screening tools):
Outcomes reported will include sensitivity, specificity,
positive predictive value, and negative predictive value,
based on child or adolescent self-report measures.
Key Questions #2 (effects of treatment) and #3 (effects
of screening): The primary outcome will be
standardized mean difference effect size based on a
continuous measure of depressive symptoms. When
multiple depression outcomes are reported, primary
outcomes as identified in each study will be given
highest priority. Then observer-rated scales will be
prioritized over self-report measures. Outcomes will be
reported as intent-to-treat analyses where possible and
will be prioritized over those presented for completers
only.
Key Question #4 (harms): Outcome reporting will be
based on harms identified from the review, but we
expect the main potential harm to be suicidal
ideation.Appraisal of risk of bias
For Key Question #1 (accuracy of screening tools), we
will use the Quality Assessment of Diagnostic Accuracy
Studies-2 tool [38]. This tool incorporates assessments
of risk of bias across four core domains: patient selec-
tion, the index test, the reference standard, and the flow
and timing of assessments. For Key Questions #2 (effects
of treatment) and #3 (effects of screening), we will use
the Cochrane Risk of Bias tool [39], which includes
assessments of six possible sources of bias related to
randomization sequence generation; allocation conceal-
ment; blinding of participants, personnel, and outcome
assessors; incomplete outcome data; selective outcome
data; and other sources of bias. In addition to these
domains, based on recent recommendations regarding
potential bias due to financial conflicts of interest
[40,41], we will code two further domains, for pharma-
ceutical industry funding, and author-industry financial
ties or employment by industry.
Synthesis of included studies
The decision as to whether data can be synthesized
using meta-analysis will be determined based on search
results. Based on the studies included in the 2009 United
States AHRQ systematic review [1] and a rough prelim-
inary search of MEDLINE conducted in October 2011,
we expect that there will be substantial heterogeneity be-
tween diagnostic accuracy studies with respect to assess-
ment timing, criterion standards, screening instruments,
and scoring thresholds. Most studies have used
population-specific cutoff thresholds based on receiver
operator characteristic curves, which yields overly opti-
mistic estimates of screening accuracy that do not repli-
cate consistently [42]. Similarly, for studies of MDD
treatment, there appears to be substantial heterogeneity
in the nature of interventions, outcome measures, and
length of follow-up. Thus, due to clinical heterogeneity,
it appears that data pooling will likely not be appropriate
and that a systematic review, rather than a meta-ana-
lysis, will be conducted. If, following the full literature
review, we find that meta-analytic data pooling is feas-
ible, then we will use appropriate models that have been
used previously in meta-analyses of diagnostic accuracy
[43], screening effectiveness [44], and treatment out-
comes from depression care interventions [45,46].
Discussion
Depression is a chronic and disabling condition that is
the leading global cause of life-years lived with disability
and the fourth leading cause of disability-adjusted life-
years, which takes into account premature mortality
[47]. Depression during childhood and adolescence can
have a devastating impact, both because of its effect on
important childhood and adolescence outcomes and
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problems into adulthood [1,15,17-19].
It is crucial that optimal depression prevention and
care programs be developed and implemented to reduce
the burden of suffering from childhood and adolescent
depression. Universal depression screening has been
recommended as a solution. Guidelines and recommen-
dations, however, are sometimes made without full con-
sideration of evidence or clinical practice realities [48].
Current guidelines for the management of childhood
and adolescent depression do not all agree about
whether universal screening should be conducted [2-4],
and depression screening among children and adoles-
cents has been implemented in some settings without
evidence of benefit [26-32].
Although screening is sometimes portrayed as the only
alternative to simply ignoring depression [49], research-
ers have accumulated evidence suggesting that patients
may benefit more by investing resources into improving
programs to better manage depression rather than seek-
ing to identify otherwise unidentified patients, many of
whom have lesser levels of symptomatology, and adding
them to an already poorly functioning depression care
system [50,51]. Indeed, Gilbody et al. found that screen-
ing does not appear to be a necessary component of ef-
fective collaborative care programs for depression in
primary care [46]. At this juncture, we know very little
about potential benefits of depression screening in child-
hood and adolescence versus potential harms. A real
danger is that implementation of routine screening with-
out evidence of how this is best done or whether it will
benefit patients could result in overtreatment of depres-
sion due to the prescription of antidepressants based on
positive screens without follow-up diagnostic interviews
on the one hand, and the continued inadequate treat-
ment of children and adolescents with MDD on the
other because resources are consumed by attempting to
find new cases rather than providing adequate treatment
to children and adolescents who are otherwise identified.
The proposed systematic review will determine
whether there is sufficient evidence to support screening
for depression in childhood and adolescence. The con-
clusions drawn from this systematic review, once disse-
minated to policy-makers, health care providers, and
researchers, will allow decisions to be made about
whether screening programs are likely to benefit chil-
dren and adolescents.Additional files
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